Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with non-small cell lung cancer (NSCLC) that is confirmed by a tissue or cell sample, and it is either at an advanced stage (Stage IV), at Stage III but not suitable for surgery or combined radiation and chemotherapy, or has come back after previous surgery with no chance of cure
- Your cancer has a specific genetic change called an ALK rearrangement
- Your body is healthy enough to tolerate the drug alectinib, and you have already been tolerating it well
- After 2–3 months of treatment with alectinib, your cancer has either stayed stable or partially shrunk
- You have no more than 5 active tumour spots (plus or minus chest lymph nodes) showing up on a special type of scan called an 18F-FDG-PET scan after starting alectinib
- All active tumour spots can be safely targeted with specific types of focused radiation treatment (confirm with trial site)
- Your body is healthy enough to tolerate radiation treatment, including meeting safety limits for nearby healthy organs
- You have a general health/activity level score of 0, 1, or 2 on a standard medical scale (meaning you are able to care for yourself and are not completely inactive)
- If your lungs are being targeted for radiation, your lung breathing capacity meets a minimum threshold (confirm with trial site)
- You are 20 years of age or older
- Your tumours can be measured using standard medical imaging criteria
- You are willing and able to sign a consent form agreeing to take part in the study
Who may not be able to join:
- Your cancer has spread to the membranes surrounding the brain or spinal cord, or has been found in the fluid around the spine
- You still have cancer-related fluid build-up around the lungs, heart, or abdomen after completing the initial alectinib treatment
- Your cancer got worse (progressed) during the first 2–3 months of alectinib treatment
- You have previously received targeted therapy (TKI), chemotherapy, or immunotherapy for advanced NSCLC (although prior chemotherapy for early-stage NSCLC is allowed)
- You have previously had radiation treatment for NSCLC at any stage
- You have had radiation treatment for any other cancer within the last 3 years that could interfere with the radiation planned in this trial
- Your life expectancy is estimated to be less than 6 months
- You are unable to understand the study information or follow the study procedures
- You have a history of or currently have a lung condition involving inflammation or scarring of lung tissue (such as interstitial lung disease, pneumonitis, or pulmonary fibrosis)
- You are pregnant or breastfeeding; participants must also agree to use effective contraception during the study and for 3 months after treatment ends
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Karin Lindberg, MD, PhD, Karolinska University Hospital
Phone: +46851770000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Toxicity (safety); Progression free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.